Progyny, Inc.
Progyny, Inc. PGNY Peers
See (PGNY) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Information Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PGNY | $20.52 | -1.77% | 1.8B | 36.00 | $0.57 | N/A |
| VEEV | $233.00 | -1.07% | 38B | 54.06 | $4.31 | N/A |
| GEHC | $69.16 | -0.40% | 31.7B | 14.53 | $4.76 | +0.19% |
| GEHCV | $56.00 | -4.08% | 25.5B | N/A | N/A | +0.19% |
| DOCS | $51.02 | -0.47% | 9.6B | 45.96 | $1.11 | N/A |
| SGFY | $30.49 | +0.07% | 8.9B | 70.91 | $0.43 | N/A |
| HQY | $99.01 | -1.07% | 8.6B | 90.83 | $1.09 | N/A |
| RCM | $14.31 | N/A | 6B | -102.21 | -$0.14 | N/A |
| BTSGU | $80.41 | -0.30% | 4B | N/A | N/A | N/A |
| BTSG | $23.23 | +1.35% | 4B | 86.04 | $0.27 | N/A |
Stock Comparison
PGNY vs VEEV Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, VEEV has a market cap of 38B. Regarding current trading prices, PGNY is priced at $20.52, while VEEV trades at $233.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas VEEV's P/E ratio is 54.06. In terms of profitability, PGNY's ROE is +0.12%, compared to VEEV's ROE of +0.13%. Regarding short-term risk, PGNY is more volatile compared to VEEV. This indicates potentially higher risk in terms of short-term price fluctuations for PGNY.
PGNY vs GEHC Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, GEHC has a market cap of 31.7B. Regarding current trading prices, PGNY is priced at $20.52, while GEHC trades at $69.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas GEHC's P/E ratio is 14.53. In terms of profitability, PGNY's ROE is +0.12%, compared to GEHC's ROE of +0.26%. Regarding short-term risk, PGNY is more volatile compared to GEHC. This indicates potentially higher risk in terms of short-term price fluctuations for PGNY.
PGNY vs GEHCV Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, GEHCV has a market cap of 25.5B. Regarding current trading prices, PGNY is priced at $20.52, while GEHCV trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas GEHCV's P/E ratio is N/A. In terms of profitability, PGNY's ROE is +0.12%, compared to GEHCV's ROE of +0.26%. Regarding short-term risk, PGNY is less volatile compared to GEHCV. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs DOCS Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, DOCS has a market cap of 9.6B. Regarding current trading prices, PGNY is priced at $20.52, while DOCS trades at $51.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas DOCS's P/E ratio is 45.96. In terms of profitability, PGNY's ROE is +0.12%, compared to DOCS's ROE of +0.22%. Regarding short-term risk, PGNY is less volatile compared to DOCS. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs SGFY Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, SGFY has a market cap of 8.9B. Regarding current trading prices, PGNY is priced at $20.52, while SGFY trades at $30.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas SGFY's P/E ratio is 70.91. In terms of profitability, PGNY's ROE is +0.12%, compared to SGFY's ROE of -0.15%. Regarding short-term risk, PGNY is more volatile compared to SGFY. This indicates potentially higher risk in terms of short-term price fluctuations for PGNY.
PGNY vs HQY Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, HQY has a market cap of 8.6B. Regarding current trading prices, PGNY is priced at $20.52, while HQY trades at $99.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas HQY's P/E ratio is 90.83. In terms of profitability, PGNY's ROE is +0.12%, compared to HQY's ROE of +0.05%. Regarding short-term risk, PGNY is less volatile compared to HQY. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs RCM Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, RCM has a market cap of 6B. Regarding current trading prices, PGNY is priced at $20.52, while RCM trades at $14.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas RCM's P/E ratio is -102.21. In terms of profitability, PGNY's ROE is +0.12%, compared to RCM's ROE of -0.02%. Regarding short-term risk, PGNY is more volatile compared to RCM. This indicates potentially higher risk in terms of short-term price fluctuations for PGNY.
PGNY vs BTSGU Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, BTSGU has a market cap of 4B. Regarding current trading prices, PGNY is priced at $20.52, while BTSGU trades at $80.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas BTSGU's P/E ratio is N/A. In terms of profitability, PGNY's ROE is +0.12%, compared to BTSGU's ROE of +0.03%. Regarding short-term risk, PGNY is more volatile compared to BTSGU. This indicates potentially higher risk in terms of short-term price fluctuations for PGNY.
PGNY vs BTSG Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, BTSG has a market cap of 4B. Regarding current trading prices, PGNY is priced at $20.52, while BTSG trades at $23.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas BTSG's P/E ratio is 86.04. In terms of profitability, PGNY's ROE is +0.12%, compared to BTSG's ROE of +0.03%. Regarding short-term risk, PGNY is less volatile compared to BTSG. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs ONEM Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, ONEM has a market cap of 3.4B. Regarding current trading prices, PGNY is priced at $20.52, while ONEM trades at $16.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas ONEM's P/E ratio is -7.77. In terms of profitability, PGNY's ROE is +0.12%, compared to ONEM's ROE of -0.24%. Regarding short-term risk, PGNY is less volatile compared to ONEM. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs PRVA Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, PRVA has a market cap of 2.8B. Regarding current trading prices, PGNY is priced at $20.52, while PRVA trades at $22.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas PRVA's P/E ratio is 190.50. In terms of profitability, PGNY's ROE is +0.12%, compared to PRVA's ROE of +0.02%. Regarding short-term risk, PGNY is less volatile compared to PRVA. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs WGS Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, WGS has a market cap of 2B. Regarding current trading prices, PGNY is priced at $20.52, while WGS trades at $71.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas WGS's P/E ratio is -51.51. In terms of profitability, PGNY's ROE is +0.12%, compared to WGS's ROE of -0.17%. Regarding short-term risk, PGNY is less volatile compared to WGS. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs PINC Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, PINC has a market cap of 1.9B. Regarding current trading prices, PGNY is priced at $20.52, while PINC trades at $23.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas PINC's P/E ratio is 22.61. In terms of profitability, PGNY's ROE is +0.12%, compared to PINC's ROE of +0.03%. Regarding short-term risk, PGNY is more volatile compared to PINC. This indicates potentially higher risk in terms of short-term price fluctuations for PGNY.
PGNY vs CERT Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, CERT has a market cap of 1.9B. Regarding current trading prices, PGNY is priced at $20.52, while CERT trades at $11.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas CERT's P/E ratio is -571.00. In terms of profitability, PGNY's ROE is +0.12%, compared to CERT's ROE of -0.00%. Regarding short-term risk, PGNY is less volatile compared to CERT. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs NXGN Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, NXGN has a market cap of 1.6B. Regarding current trading prices, PGNY is priced at $20.52, while NXGN trades at $23.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas NXGN's P/E ratio is -266.00. In terms of profitability, PGNY's ROE is +0.12%, compared to NXGN's ROE of +0.03%. Regarding short-term risk, PGNY is more volatile compared to NXGN. This indicates potentially higher risk in terms of short-term price fluctuations for PGNY.
PGNY vs SDGR Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, SDGR has a market cap of 1.6B. Regarding current trading prices, PGNY is priced at $20.52, while SDGR trades at $21.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas SDGR's P/E ratio is -8.14. In terms of profitability, PGNY's ROE is +0.12%, compared to SDGR's ROE of -0.45%. Regarding short-term risk, PGNY is less volatile compared to SDGR. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs PHR Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, PHR has a market cap of 1.4B. Regarding current trading prices, PGNY is priced at $20.52, while PHR trades at $24.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas PHR's P/E ratio is -23.59. In terms of profitability, PGNY's ROE is +0.12%, compared to PHR's ROE of -0.23%. Regarding short-term risk, PGNY is less volatile compared to PHR. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs AGTI Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, AGTI has a market cap of 1.4B. Regarding current trading prices, PGNY is priced at $20.52, while AGTI trades at $10.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas AGTI's P/E ratio is -71.79. In terms of profitability, PGNY's ROE is +0.12%, compared to AGTI's ROE of -0.03%. Regarding short-term risk, PGNY is more volatile compared to AGTI. This indicates potentially higher risk in terms of short-term price fluctuations for PGNY.
PGNY vs GDRX Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, GDRX has a market cap of 1.3B. Regarding current trading prices, PGNY is priced at $20.52, while GDRX trades at $3.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas GDRX's P/E ratio is 53.43. In terms of profitability, PGNY's ROE is +0.12%, compared to GDRX's ROE of +0.07%. Regarding short-term risk, PGNY is less volatile compared to GDRX. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs OMCL Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, OMCL has a market cap of 1.3B. Regarding current trading prices, PGNY is priced at $20.52, while OMCL trades at $28.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas OMCL's P/E ratio is 61.37. In terms of profitability, PGNY's ROE is +0.12%, compared to OMCL's ROE of +0.02%. Regarding short-term risk, PGNY is less volatile compared to OMCL. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs TDOC Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, TDOC has a market cap of 1.2B. Regarding current trading prices, PGNY is priced at $20.52, while TDOC trades at $6.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas TDOC's P/E ratio is -1.15. In terms of profitability, PGNY's ROE is +0.12%, compared to TDOC's ROE of -0.68%. Regarding short-term risk, PGNY is less volatile compared to TDOC. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs TXG Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, TXG has a market cap of 1B. Regarding current trading prices, PGNY is priced at $20.52, while TXG trades at $8.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas TXG's P/E ratio is -6.28. In terms of profitability, PGNY's ROE is +0.12%, compared to TXG's ROE of -0.22%. Regarding short-term risk, PGNY is less volatile compared to TXG. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs NUTX Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, NUTX has a market cap of 890.2M. Regarding current trading prices, PGNY is priced at $20.52, while NUTX trades at $159.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas NUTX's P/E ratio is 12.95. In terms of profitability, PGNY's ROE is +0.12%, compared to NUTX's ROE of +0.71%. Regarding short-term risk, PGNY is less volatile compared to NUTX. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs EVH Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, EVH has a market cap of 846.5M. Regarding current trading prices, PGNY is priced at $20.52, while EVH trades at $7.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas EVH's P/E ratio is -5.91. In terms of profitability, PGNY's ROE is +0.12%, compared to EVH's ROE of -0.11%. Regarding short-term risk, PGNY is less volatile compared to EVH. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs HSTM Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, HSTM has a market cap of 834.9M. Regarding current trading prices, PGNY is priced at $20.52, while HSTM trades at $27.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas HSTM's P/E ratio is 43.41. In terms of profitability, PGNY's ROE is +0.12%, compared to HSTM's ROE of +0.05%. Regarding short-term risk, PGNY is less volatile compared to HSTM. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs SLP Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, SLP has a market cap of 664.6M. Regarding current trading prices, PGNY is priced at $20.52, while SLP trades at $33.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas SLP's P/E ratio is 91.79. In terms of profitability, PGNY's ROE is +0.12%, compared to SLP's ROE of +0.04%. Regarding short-term risk, PGNY is less volatile compared to SLP. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs MPLN-WT Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, MPLN-WT has a market cap of 625.2M. Regarding current trading prices, PGNY is priced at $20.52, while MPLN-WT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas MPLN-WT's P/E ratio is N/A. In terms of profitability, PGNY's ROE is +0.12%, compared to MPLN-WT's ROE of -5.18%. Regarding short-term risk, PGNY is less volatile compared to MPLN-WT. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs ACCD Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, ACCD has a market cap of 575.6M. Regarding current trading prices, PGNY is priced at $20.52, while ACCD trades at $7.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas ACCD's P/E ratio is -3.08. In terms of profitability, PGNY's ROE is +0.12%, compared to ACCD's ROE of -0.45%. Regarding short-term risk, PGNY is more volatile compared to ACCD. This indicates potentially higher risk in terms of short-term price fluctuations for PGNY.
PGNY vs CCLDP Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, CCLDP has a market cap of 566.6M. Regarding current trading prices, PGNY is priced at $20.52, while CCLDP trades at $19.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas CCLDP's P/E ratio is N/A. In terms of profitability, PGNY's ROE is +0.12%, compared to CCLDP's ROE of +0.21%. Regarding short-term risk, PGNY is more volatile compared to CCLDP. This indicates potentially higher risk in terms of short-term price fluctuations for PGNY.
PGNY vs SHCR Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, SHCR has a market cap of 531.8M. Regarding current trading prices, PGNY is priced at $20.52, while SHCR trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas SHCR's P/E ratio is -3.76. In terms of profitability, PGNY's ROE is +0.12%, compared to SHCR's ROE of -0.29%. Regarding short-term risk, PGNY is more volatile compared to SHCR. This indicates potentially higher risk in terms of short-term price fluctuations for PGNY.
PGNY vs CTEV Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, CTEV has a market cap of 436.6M. Regarding current trading prices, PGNY is priced at $20.52, while CTEV trades at $26.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas CTEV's P/E ratio is -0.36. In terms of profitability, PGNY's ROE is +0.12%, compared to CTEV's ROE of -5.18%. Regarding short-term risk, PGNY is less volatile compared to CTEV. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs SLGCW Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, SLGCW has a market cap of 396.2M. Regarding current trading prices, PGNY is priced at $20.52, while SLGCW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas SLGCW's P/E ratio is -0.16. In terms of profitability, PGNY's ROE is +0.12%, compared to SLGCW's ROE of -0.09%. Regarding short-term risk, PGNY is less volatile compared to SLGCW. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs SLGC Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, SLGC has a market cap of 396.2M. Regarding current trading prices, PGNY is priced at $20.52, while SLGC trades at $2.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas SLGC's P/E ratio is -3.04. In terms of profitability, PGNY's ROE is +0.12%, compared to SLGC's ROE of -0.09%. Regarding short-term risk, PGNY is less volatile compared to SLGC. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs MPLN Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, MPLN has a market cap of 375M. Regarding current trading prices, PGNY is priced at $20.52, while MPLN trades at $23.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas MPLN's P/E ratio is -0.23. In terms of profitability, PGNY's ROE is +0.12%, compared to MPLN's ROE of -5.18%. Regarding short-term risk, PGNY is less volatile compared to MPLN. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs TBRG Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, TBRG has a market cap of 356.5M. Regarding current trading prices, PGNY is priced at $20.52, while TBRG trades at $23.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas TBRG's P/E ratio is -19.45. In terms of profitability, PGNY's ROE is +0.12%, compared to TBRG's ROE of -0.10%. Regarding short-term risk, PGNY is less volatile compared to TBRG. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs SPOK Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, SPOK has a market cap of 326.5M. Regarding current trading prices, PGNY is priced at $20.52, while SPOK trades at $15.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas SPOK's P/E ratio is 20.61. In terms of profitability, PGNY's ROE is +0.12%, compared to SPOK's ROE of +0.10%. Regarding short-term risk, PGNY is less volatile compared to SPOK. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs DH Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, DH has a market cap of 324.2M. Regarding current trading prices, PGNY is priced at $20.52, while DH trades at $3.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas DH's P/E ratio is -0.68. In terms of profitability, PGNY's ROE is +0.12%, compared to DH's ROE of -1.07%. Regarding short-term risk, PGNY is less volatile compared to DH. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs NRC Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, NRC has a market cap of 309.7M. Regarding current trading prices, PGNY is priced at $20.52, while NRC trades at $13.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas NRC's P/E ratio is 13.32. In terms of profitability, PGNY's ROE is +0.12%, compared to NRC's ROE of +0.71%. Regarding short-term risk, PGNY is less volatile compared to NRC. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs TRHC Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, TRHC has a market cap of 284M. Regarding current trading prices, PGNY is priced at $20.52, while TRHC trades at $10.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas TRHC's P/E ratio is -4.27. In terms of profitability, PGNY's ROE is +0.12%, compared to TRHC's ROE of +121.31%. Regarding short-term risk, PGNY is more volatile compared to TRHC. This indicates potentially higher risk in terms of short-term price fluctuations for PGNY.
PGNY vs HCAT Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, HCAT has a market cap of 254M. Regarding current trading prices, PGNY is priced at $20.52, while HCAT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas HCAT's P/E ratio is -3.17. In terms of profitability, PGNY's ROE is +0.12%, compared to HCAT's ROE of -0.20%. Regarding short-term risk, PGNY is less volatile compared to HCAT. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs SMFR Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, SMFR has a market cap of 246.4M. Regarding current trading prices, PGNY is priced at $20.52, while SMFR trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas SMFR's P/E ratio is N/A. In terms of profitability, PGNY's ROE is +0.12%, compared to SMFR's ROE of -0.17%. Regarding short-term risk, PGNY is less volatile compared to SMFR. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs OPRX Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, OPRX has a market cap of 215.5M. Regarding current trading prices, PGNY is priced at $20.52, while OPRX trades at $11.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas OPRX's P/E ratio is -13.87. In terms of profitability, PGNY's ROE is +0.12%, compared to OPRX's ROE of -0.13%. Regarding short-term risk, PGNY is less volatile compared to OPRX. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs SOPH Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, SOPH has a market cap of 190.5M. Regarding current trading prices, PGNY is priced at $20.52, while SOPH trades at $2.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas SOPH's P/E ratio is -2.85. In terms of profitability, PGNY's ROE is +0.12%, compared to SOPH's ROE of -0.63%. Regarding short-term risk, PGNY is less volatile compared to SOPH. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs EUDA Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, EUDA has a market cap of 139.7M. Regarding current trading prices, PGNY is priced at $20.52, while EUDA trades at $3.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas EUDA's P/E ratio is -6.96. In terms of profitability, PGNY's ROE is +0.12%, compared to EUDA's ROE of +3.05%. Regarding short-term risk, PGNY is less volatile compared to EUDA. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs CPSI Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, CPSI has a market cap of 133.7M. Regarding current trading prices, PGNY is priced at $20.52, while CPSI trades at $9.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas CPSI's P/E ratio is -183.80. In terms of profitability, PGNY's ROE is +0.12%, compared to CPSI's ROE of -0.18%. Regarding short-term risk, PGNY is less volatile compared to CPSI. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs AMWL Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, AMWL has a market cap of 117.3M. Regarding current trading prices, PGNY is priced at $20.52, while AMWL trades at $7.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas AMWL's P/E ratio is -0.73. In terms of profitability, PGNY's ROE is +0.12%, compared to AMWL's ROE of -0.48%. Regarding short-term risk, PGNY is less volatile compared to AMWL. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs AUGX Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, AUGX has a market cap of 115.9M. Regarding current trading prices, PGNY is priced at $20.52, while AUGX trades at $2.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas AUGX's P/E ratio is -4.99. In terms of profitability, PGNY's ROE is +0.12%, compared to AUGX's ROE of -1.82%. Regarding short-term risk, PGNY is more volatile compared to AUGX. This indicates potentially higher risk in terms of short-term price fluctuations for PGNY.
PGNY vs SY Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, SY has a market cap of 110.7M. Regarding current trading prices, PGNY is priced at $20.52, while SY trades at $0.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas SY's P/E ratio is -1.05. In terms of profitability, PGNY's ROE is +0.12%, compared to SY's ROE of -0.26%. Regarding short-term risk, PGNY is less volatile compared to SY. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs CCLDO Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, CCLDO has a market cap of 84.2M. Regarding current trading prices, PGNY is priced at $20.52, while CCLDO trades at $19.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas CCLDO's P/E ratio is N/A. In terms of profitability, PGNY's ROE is +0.12%, compared to CCLDO's ROE of +0.21%. Regarding short-term risk, PGNY is more volatile compared to CCLDO. This indicates potentially higher risk in terms of short-term price fluctuations for PGNY.
PGNY vs CCLD Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, CCLD has a market cap of 84.2M. Regarding current trading prices, PGNY is priced at $20.52, while CCLD trades at $1.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas CCLD's P/E ratio is -9.05. In terms of profitability, PGNY's ROE is +0.12%, compared to CCLD's ROE of +0.21%. Regarding short-term risk, PGNY is less volatile compared to CCLD. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs FORA Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, FORA has a market cap of 64.6M. Regarding current trading prices, PGNY is priced at $20.52, while FORA trades at $2.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas FORA's P/E ratio is -17.25. In terms of profitability, PGNY's ROE is +0.12%, compared to FORA's ROE of -0.13%. Regarding short-term risk, PGNY is less volatile compared to FORA. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs BEAT Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, BEAT has a market cap of 56.1M. Regarding current trading prices, PGNY is priced at $20.52, while BEAT trades at $1.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas BEAT's P/E ratio is -2.24. In terms of profitability, PGNY's ROE is +0.12%, compared to BEAT's ROE of -3.58%. Regarding short-term risk, PGNY is less volatile compared to BEAT. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs BEATW Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, BEATW has a market cap of 56.1M. Regarding current trading prices, PGNY is priced at $20.52, while BEATW trades at $0.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas BEATW's P/E ratio is -1.09. In terms of profitability, PGNY's ROE is +0.12%, compared to BEATW's ROE of -3.58%. Regarding short-term risk, PGNY is more volatile compared to BEATW. This indicates potentially higher risk in terms of short-term price fluctuations for PGNY.
PGNY vs SNCE Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, SNCE has a market cap of 34.7M. Regarding current trading prices, PGNY is priced at $20.52, while SNCE trades at $5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas SNCE's P/E ratio is -0.27. In terms of profitability, PGNY's ROE is +0.12%, compared to SNCE's ROE of -0.59%. Regarding short-term risk, PGNY is more volatile compared to SNCE. This indicates potentially higher risk in terms of short-term price fluctuations for PGNY.
PGNY vs AKLI Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, AKLI has a market cap of 34.1M. Regarding current trading prices, PGNY is priced at $20.52, while AKLI trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas AKLI's P/E ratio is -0.71. In terms of profitability, PGNY's ROE is +0.12%, compared to AKLI's ROE of -0.74%. Regarding short-term risk, PGNY is more volatile compared to AKLI. This indicates potentially higher risk in terms of short-term price fluctuations for PGNY.
PGNY vs SHLT Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, SHLT has a market cap of 33.6M. Regarding current trading prices, PGNY is priced at $20.52, while SHLT trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas SHLT's P/E ratio is -3.87. In terms of profitability, PGNY's ROE is +0.12%, compared to SHLT's ROE of -0.09%. Regarding short-term risk, PGNY is more volatile compared to SHLT. This indicates potentially higher risk in terms of short-term price fluctuations for PGNY.
PGNY vs SHCRW Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, SHCRW has a market cap of 32.5M. Regarding current trading prices, PGNY is priced at $20.52, while SHCRW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas SHCRW's P/E ratio is -0.00. In terms of profitability, PGNY's ROE is +0.12%, compared to SHCRW's ROE of -0.29%. Regarding short-term risk, PGNY is less volatile compared to SHCRW. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs RNLX Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, RNLX has a market cap of 22.5M. Regarding current trading prices, PGNY is priced at $20.52, while RNLX trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas RNLX's P/E ratio is -0.33. In terms of profitability, PGNY's ROE is +0.12%, compared to RNLX's ROE of +2.93%. Regarding short-term risk, PGNY is less volatile compared to RNLX. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs LIFW Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, LIFW has a market cap of 22.4M. Regarding current trading prices, PGNY is priced at $20.52, while LIFW trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas LIFW's P/E ratio is -0.02. In terms of profitability, PGNY's ROE is +0.12%, compared to LIFW's ROE of -3.08%. Regarding short-term risk, PGNY is more volatile compared to LIFW. This indicates potentially higher risk in terms of short-term price fluctuations for PGNY.
PGNY vs MGRX Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, MGRX has a market cap of 18.6M. Regarding current trading prices, PGNY is priced at $20.52, while MGRX trades at $1.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas MGRX's P/E ratio is -0.37. In terms of profitability, PGNY's ROE is +0.12%, compared to MGRX's ROE of -0.73%. Regarding short-term risk, PGNY is less volatile compared to MGRX. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs BFRG Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, BFRG has a market cap of 17.4M. Regarding current trading prices, PGNY is priced at $20.52, while BFRG trades at $1.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas BFRG's P/E ratio is -2.31. In terms of profitability, PGNY's ROE is +0.12%, compared to BFRG's ROE of -1.63%. Regarding short-term risk, PGNY is less volatile compared to BFRG. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs VSEEW Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, VSEEW has a market cap of 17.1M. Regarding current trading prices, PGNY is priced at $20.52, while VSEEW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas VSEEW's P/E ratio is N/A. In terms of profitability, PGNY's ROE is +0.12%, compared to VSEEW's ROE of -6.10%. Regarding short-term risk, PGNY is more volatile compared to VSEEW. This indicates potentially higher risk in terms of short-term price fluctuations for PGNY.
PGNY vs VSEE Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, VSEE has a market cap of 17.1M. Regarding current trading prices, PGNY is priced at $20.52, while VSEE trades at $1.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas VSEE's P/E ratio is -13.62. In terms of profitability, PGNY's ROE is +0.12%, compared to VSEE's ROE of -6.10%. Regarding short-term risk, PGNY is less volatile compared to VSEE. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs BBLN Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, BBLN has a market cap of 14.1M. Regarding current trading prices, PGNY is priced at $20.52, while BBLN trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas BBLN's P/E ratio is -0.04. In terms of profitability, PGNY's ROE is +0.12%, compared to BBLN's ROE of +4.89%. Regarding short-term risk, PGNY is less volatile compared to BBLN. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs INOV Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, INOV has a market cap of 13.8M. Regarding current trading prices, PGNY is priced at $20.52, while INOV trades at $31.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas INOV's P/E ratio is 16.77. In terms of profitability, PGNY's ROE is +0.12%, compared to INOV's ROE of +0.03%. Regarding short-term risk, PGNY is more volatile compared to INOV. This indicates potentially higher risk in terms of short-term price fluctuations for PGNY.
PGNY vs ONMD Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, ONMD has a market cap of 12.5M. Regarding current trading prices, PGNY is priced at $20.52, while ONMD trades at $0.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas ONMD's P/E ratio is -1.20. In terms of profitability, PGNY's ROE is +0.12%, compared to ONMD's ROE of +0.60%. Regarding short-term risk, PGNY is less volatile compared to ONMD. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs MSPR Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, MSPR has a market cap of 12.2M. Regarding current trading prices, PGNY is priced at $20.52, while MSPR trades at $1.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas MSPR's P/E ratio is N/A. In terms of profitability, PGNY's ROE is +0.12%, compared to MSPR's ROE of -3.08%. Regarding short-term risk, PGNY is less volatile compared to MSPR. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs SCNX Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, SCNX has a market cap of 11.5M. Regarding current trading prices, PGNY is priced at $20.52, while SCNX trades at $0.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas SCNX's P/E ratio is 1.33. In terms of profitability, PGNY's ROE is +0.12%, compared to SCNX's ROE of +0.19%. Regarding short-term risk, PGNY is less volatile compared to SCNX. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs ETAO Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, ETAO has a market cap of 9.8M. Regarding current trading prices, PGNY is priced at $20.52, while ETAO trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas ETAO's P/E ratio is -0.01. In terms of profitability, PGNY's ROE is +0.12%, compared to ETAO's ROE of -13.69%. Regarding short-term risk, PGNY is less volatile compared to ETAO. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs STRM Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, STRM has a market cap of 9.3M. Regarding current trading prices, PGNY is priced at $20.52, while STRM trades at $2.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas STRM's P/E ratio is -0.85. In terms of profitability, PGNY's ROE is +0.12%, compared to STRM's ROE of -0.68%. Regarding short-term risk, PGNY is less volatile compared to STRM. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs HLTH Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, HLTH has a market cap of 6.9M. Regarding current trading prices, PGNY is priced at $20.52, while HLTH trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas HLTH's P/E ratio is -0.02. In terms of profitability, PGNY's ROE is +0.12%, compared to HLTH's ROE of -1.04%. Regarding short-term risk, PGNY is less volatile compared to HLTH. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs OTRK Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, OTRK has a market cap of 6.6M. Regarding current trading prices, PGNY is priced at $20.52, while OTRK trades at $1.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas OTRK's P/E ratio is -0.09. In terms of profitability, PGNY's ROE is +0.12%, compared to OTRK's ROE of -1.76%. Regarding short-term risk, PGNY is less volatile compared to OTRK. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs ZCMD Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, ZCMD has a market cap of 6M. Regarding current trading prices, PGNY is priced at $20.52, while ZCMD trades at $1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas ZCMD's P/E ratio is -9.58. In terms of profitability, PGNY's ROE is +0.12%, compared to ZCMD's ROE of -0.03%. Regarding short-term risk, PGNY is less volatile compared to ZCMD. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs UPH Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, UPH has a market cap of 5.3M. Regarding current trading prices, PGNY is priced at $20.52, while UPH trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas UPH's P/E ratio is -0.07. In terms of profitability, PGNY's ROE is +0.12%, compared to UPH's ROE of -1.05%. Regarding short-term risk, PGNY is less volatile compared to UPH. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs EUDAW Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, EUDAW has a market cap of 5.2M. Regarding current trading prices, PGNY is priced at $20.52, while EUDAW trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas EUDAW's P/E ratio is N/A. In terms of profitability, PGNY's ROE is +0.12%, compared to EUDAW's ROE of +3.05%. Regarding short-term risk, PGNY is more volatile compared to EUDAW. This indicates potentially higher risk in terms of short-term price fluctuations for PGNY.
PGNY vs PEARW Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, PEARW has a market cap of 4.1M. Regarding current trading prices, PGNY is priced at $20.52, while PEARW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas PEARW's P/E ratio is -0.00. In terms of profitability, PGNY's ROE is +0.12%, compared to PEARW's ROE of -0.39%. Regarding short-term risk, PGNY is less volatile compared to PEARW. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs PEAR Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, PEAR has a market cap of 4.1M. Regarding current trading prices, PGNY is priced at $20.52, while PEAR trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas PEAR's P/E ratio is -0.08. In terms of profitability, PGNY's ROE is +0.12%, compared to PEAR's ROE of -0.39%. Regarding short-term risk, PGNY is less volatile compared to PEAR. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs ACON Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, ACON has a market cap of 3.9M. Regarding current trading prices, PGNY is priced at $20.52, while ACON trades at $6.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas ACON's P/E ratio is -0.58. In terms of profitability, PGNY's ROE is +0.12%, compared to ACON's ROE of -1.27%. Regarding short-term risk, PGNY is less volatile compared to ACON. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs FOXO Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, FOXO has a market cap of 3.4M. Regarding current trading prices, PGNY is priced at $20.52, while FOXO trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas FOXO's P/E ratio is -0.07. In terms of profitability, PGNY's ROE is +0.12%, compared to FOXO's ROE of -0.01%. Regarding short-term risk, PGNY is less volatile compared to FOXO. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs HCTI Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, HCTI has a market cap of 2.4M. Regarding current trading prices, PGNY is priced at $20.52, while HCTI trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas HCTI's P/E ratio is -0.01. In terms of profitability, PGNY's ROE is +0.12%, compared to HCTI's ROE of +2.95%. Regarding short-term risk, PGNY is less volatile compared to HCTI. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs WGSWW Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, WGSWW has a market cap of 1.9M. Regarding current trading prices, PGNY is priced at $20.52, while WGSWW trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas WGSWW's P/E ratio is N/A. In terms of profitability, PGNY's ROE is +0.12%, compared to WGSWW's ROE of -0.17%. Regarding short-term risk, PGNY is less volatile compared to WGSWW. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs CMAX Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, CMAX has a market cap of 1.6M. Regarding current trading prices, PGNY is priced at $20.52, while CMAX trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas CMAX's P/E ratio is -0.00. In terms of profitability, PGNY's ROE is +0.12%, compared to CMAX's ROE of +30.94%. Regarding short-term risk, PGNY is less volatile compared to CMAX. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs ICCT Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, ICCT has a market cap of 1.5M. Regarding current trading prices, PGNY is priced at $20.52, while ICCT trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas ICCT's P/E ratio is -0.01. In terms of profitability, PGNY's ROE is +0.12%, compared to ICCT's ROE of -14.51%. Regarding short-term risk, PGNY is less volatile compared to ICCT. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs WORX Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, WORX has a market cap of 1.5M. Regarding current trading prices, PGNY is priced at $20.52, while WORX trades at $0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas WORX's P/E ratio is -0.45. In terms of profitability, PGNY's ROE is +0.12%, compared to WORX's ROE of -0.32%. Regarding short-term risk, PGNY is less volatile compared to WORX. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs LIFWZ Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, LIFWZ has a market cap of 1.3M. Regarding current trading prices, PGNY is priced at $20.52, while LIFWZ trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas LIFWZ's P/E ratio is N/A. In terms of profitability, PGNY's ROE is +0.12%, compared to LIFWZ's ROE of -3.08%. Regarding short-term risk, PGNY is more volatile compared to LIFWZ. This indicates potentially higher risk in terms of short-term price fluctuations for PGNY.
PGNY vs OTRKP Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, OTRKP has a market cap of 1M. Regarding current trading prices, PGNY is priced at $20.52, while OTRKP trades at $0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas OTRKP's P/E ratio is -0.08. In terms of profitability, PGNY's ROE is +0.12%, compared to OTRKP's ROE of -1.76%. Regarding short-term risk, PGNY is less volatile compared to OTRKP. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs KERNW Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, KERNW has a market cap of 162.3K. Regarding current trading prices, PGNY is priced at $20.52, while KERNW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas KERNW's P/E ratio is -0.00. In terms of profitability, PGNY's ROE is +0.12%, compared to KERNW's ROE of -2.22%. Regarding short-term risk, PGNY is less volatile compared to KERNW. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs KERN Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, KERN has a market cap of 162.3K. Regarding current trading prices, PGNY is priced at $20.52, while KERN trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas KERN's P/E ratio is -0.01. In terms of profitability, PGNY's ROE is +0.12%, compared to KERN's ROE of -2.22%. Regarding short-term risk, PGNY is less volatile compared to KERN. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs LIFWW Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, LIFWW has a market cap of 60.1K. Regarding current trading prices, PGNY is priced at $20.52, while LIFWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas LIFWW's P/E ratio is N/A. In terms of profitability, PGNY's ROE is +0.12%, compared to LIFWW's ROE of -3.08%. Regarding short-term risk, PGNY is more volatile compared to LIFWW. This indicates potentially higher risk in terms of short-term price fluctuations for PGNY.
PGNY vs MSPRZ Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, MSPRZ has a market cap of 59.5K. Regarding current trading prices, PGNY is priced at $20.52, while MSPRZ trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas MSPRZ's P/E ratio is N/A. In terms of profitability, PGNY's ROE is +0.12%, compared to MSPRZ's ROE of -3.08%. Regarding short-term risk, PGNY is less volatile compared to MSPRZ. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs CMAXW Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, CMAXW has a market cap of 36.4K. Regarding current trading prices, PGNY is priced at $20.52, while CMAXW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas CMAXW's P/E ratio is N/A. In terms of profitability, PGNY's ROE is +0.12%, compared to CMAXW's ROE of +30.94%. Regarding short-term risk, PGNY is more volatile compared to CMAXW. This indicates potentially higher risk in terms of short-term price fluctuations for PGNY.
PGNY vs ACONW Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, ACONW has a market cap of 17.5K. Regarding current trading prices, PGNY is priced at $20.52, while ACONW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas ACONW's P/E ratio is N/A. In terms of profitability, PGNY's ROE is +0.12%, compared to ACONW's ROE of -1.27%. Regarding short-term risk, PGNY is more volatile compared to ACONW. This indicates potentially higher risk in terms of short-term price fluctuations for PGNY.
PGNY vs MSPRW Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, MSPRW has a market cap of 6.2K. Regarding current trading prices, PGNY is priced at $20.52, while MSPRW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas MSPRW's P/E ratio is N/A. In terms of profitability, PGNY's ROE is +0.12%, compared to MSPRW's ROE of -3.08%. Regarding short-term risk, PGNY is less volatile compared to MSPRW. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.
PGNY vs UTRS Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, UTRS has a market cap of 888. Regarding current trading prices, PGNY is priced at $20.52, while UTRS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas UTRS's P/E ratio is N/A. In terms of profitability, PGNY's ROE is +0.12%, compared to UTRS's ROE of -1.11%. Regarding short-term risk, PGNY is more volatile compared to UTRS. This indicates potentially higher risk in terms of short-term price fluctuations for PGNY.
PGNY vs CERN Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, CERN has a market cap of 0. Regarding current trading prices, PGNY is priced at $20.52, while CERN trades at $94.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas CERN's P/E ratio is 55.84. In terms of profitability, PGNY's ROE is +0.12%, compared to CERN's ROE of +0.14%. Regarding short-term risk, PGNY is more volatile compared to CERN. This indicates potentially higher risk in terms of short-term price fluctuations for PGNY.
PGNY vs MTBCP Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, MTBCP has a market cap of 0. Regarding current trading prices, PGNY is priced at $20.52, while MTBCP trades at $26.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas MTBCP's P/E ratio is N/A. In terms of profitability, PGNY's ROE is +0.12%, compared to MTBCP's ROE of +0.21%. Regarding short-term risk, PGNY is more volatile compared to MTBCP. This indicates potentially higher risk in terms of short-term price fluctuations for PGNY.
PGNY vs CHNG Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, CHNG has a market cap of 0. Regarding current trading prices, PGNY is priced at $20.52, while CHNG trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas CHNG's P/E ratio is -152.72. In terms of profitability, PGNY's ROE is +0.12%, compared to CHNG's ROE of -0.05%. Regarding short-term risk, PGNY is more volatile compared to CHNG. This indicates potentially higher risk in terms of short-term price fluctuations for PGNY.
PGNY vs CHNGU Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, CHNGU has a market cap of 0. Regarding current trading prices, PGNY is priced at $20.52, while CHNGU trades at $73.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas CHNGU's P/E ratio is N/A. In terms of profitability, PGNY's ROE is +0.12%, compared to CHNGU's ROE of -0.05%. Regarding short-term risk, PGNY is more volatile compared to CHNGU. This indicates potentially higher risk in terms of short-term price fluctuations for PGNY.
PGNY vs MTBC Comparison
PGNY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGNY stands at 1.8B. In comparison, MTBC has a market cap of 0. Regarding current trading prices, PGNY is priced at $20.52, while MTBC trades at $3.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGNY currently has a P/E ratio of 36.00, whereas MTBC's P/E ratio is N/A. In terms of profitability, PGNY's ROE is +0.12%, compared to MTBC's ROE of +0.21%. Regarding short-term risk, PGNY is less volatile compared to MTBC. This indicates potentially lower risk in terms of short-term price fluctuations for PGNY.